factor vii baxalta 600iu prášek a rozpouštědlo pro injekční roztok
baxalta innovations gmbh, vídeň array - 3534 lidskÝ koagulaČnÍ faktor vii - prášek a rozpouštědlo pro injekční roztok - 600iu - koagulaČnÍ faktor vii
dospelin 10mg potahovaná tableta
medochemie ltd., limassol array - 17598 monohydrÁt donepezil-hydrochloridu - potahovaná tableta - 10mg - donepezil
dospelin 5mg potahovaná tableta
medochemie ltd., limassol array - 17598 monohydrÁt donepezil-hydrochloridu - potahovaná tableta - 5mg - donepezil
jidinum 100mg potahovaná tableta
medochemie ltd., limassol array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 100mg - sitagliptin
jidinum 25mg potahovaná tableta
medochemie ltd., limassol array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 25mg - sitagliptin
jidinum 50mg potahovaná tableta
medochemie ltd., limassol array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 50mg - sitagliptin
jivolar 50mg/1000mg potahovaná tableta
medochemie ltd., limassol array - 17916 monohydrÁt sitagliptin-fosfÁtu; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a sitagliptin
jivolar 50mg/850mg potahovaná tableta
medochemie ltd., limassol array - 17916 monohydrÁt sitagliptin-fosfÁtu; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a sitagliptin
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.